Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of KP-100IT in Acute Spinal Cord Injury
NCT04475224Phase 3Unknown
- Sponsor
- Kringle Pharma, Inc.
- Start
- Jul 2020
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of KP-100 in spinal cord injury (SCI), sponsored by Kringle Pharma, Inc.. Status: unknown.
02
Drugs
KP-100
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT04475224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04475224.